Vaccine for treatment of tautopathy
This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.
1. A vaccine for treating tauopathy dementia, comprising a vector as an active ingredient,
wherein the vector comprises a nucleic acid encoding a full length mutant tau protein linked to a secretory signal sequence,
wherein the full length mutant tau protein comprises a substitution mutation of an amino acid residue, P301S, at a position 301 of the amino acid sequence of SEQ ID NO: 1 of a tau protein, and
wherein the vector is a Sendai virus vector and is capable of inducing an antibody to the full length mutant tau protein in a subject in a sustained manner and is capable of reacting with phosphorylated tau protein present in the hippocampus of the subject.
2. The vaccine according to claim 1 , wherein the secretory signal sequence is a signal sequence of amyloid precursor protein or a signal sequence of CD59.
3. The vaccine according to claim 1 , wherein the vector is a Sendai virus vector in which F gene is deleted.
4. The vaccine according to claim 1 , wherein the vaccine is formulated for intranasal administration.
5. The vaccine according to claim 1 , wherein the vaccine has an effect of improving at least one symptom of abnormal social interaction, abnormal anxiety-like behavior, and impaired memory in a subject.
6. The vaccine according to claim 1 , wherein the vaccine has an effect of activating microglia in the brain of a subject and thereby suppressing the accumulation of the mutant tau protein.
7. The vaccine according to claim 1 , wherein the vector is capable of inducing an antibody to phosphorylated mutant tau protein.